UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 32

Sortiert nach

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

Diabetes, obesity & metabolism, 2009-06, Vol.11 (6), p.611-622

2009

Link zum Volltext

Verfügbarkeit prüfen

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

Diabetes, obesity & metabolism, 2008-05, Vol.10 (5), p.376-386

2008

Link zum Volltext

Verfügbarkeit prüfen

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Diabetes, obesity & metabolism, 2019-11, Vol.21 (11), p.2564-2569

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)

Diabetes, obesity & metabolism, 2015-07, Vol.17 (7), p.630-638

2015

Link zum Volltext

Verfügbarkeit prüfen

Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment

Diabetes, obesity & metabolism, 2014-10, Vol.16 (10), p.891-899

Davis, T. M. E.

2014

Link zum Volltext

Verfügbarkeit prüfen

Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial

Diabetes, obesity & metabolism, 2016-02, Vol.18 (2), p.186-190

2016

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

Diabetes, obesity & metabolism, 2011-06, Vol.13 (6), p.523-532

2011

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open‐label randomized controlled study (the SMART study)

Diabetes, obesity & metabolism, 2017-11, Vol.19 (11), p.1513-1520

2017

Link zum Volltext

Verfügbarkeit prüfen

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks

Diabetes, obesity & metabolism, 2011-06, Vol.13 (6), p.567-576

2011

Link zum Volltext

Verfügbarkeit prüfen

Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study

Diabetes, obesity & metabolism, 2015-05, Vol.17 (5), p.487-494

2015

Link zum Volltext

Verfügbarkeit prüfen

Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies

Diabetes, obesity & metabolism, 2016-12, Vol.18 (12), p.1253-1262

2016

Link zum Volltext

Verfügbarkeit prüfen

Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR‐TIMI 53 outcome study

Diabetes, obesity & metabolism, 2017-07, Vol.19 (7), p.1045-1050

2017

Link zum Volltext

Verfügbarkeit prüfen

Baseline differences in the SAVOR trial

Diabetes, obesity & metabolism, 2015-12, Vol.17 (12), p.1202-1202

2015

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis

Diabetes, obesity & metabolism, 2012-06, Vol.14 (6), p.481-492

2012

Link zum Volltext

Verfügbarkeit prüfen

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2011-09, Vol.13 (9), p.850-858

2011

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin and Heart Failure in the SAVOR-TIMI 53 Trial: Reflections on the Bradford Hill Criteria

Revista española de cardiología (English ed.), 2017-12, Vol.70 (12), p.1143-1144

2017

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin efficacy

Diabetes, obesity & metabolism, 2010-08, Vol.12 (8), p.734-734

Valiquette, G.

2010

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin: A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes

Cardiology in review, 2010-07, Vol.18 (4), p.213-217

2010

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

IDrugs : the investigational drugs journal, 2008-12, Vol.11 (12), p.906

Gallwitz, Baptist

2008

Link zum Volltext

Verfügbarkeit prüfen

No heart risk--or benefit--from diabetes drug Onglyza

Harvard heart letter, 2013-12, Vol.24 (4), p.8

2013

Link zum Volltext

Verfügbarkeit prüfen

DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia

Pharmazie in unserer Zeit, 2010-03, Vol.39 (2), p.114-118

Gallwitz, Baptist

2010

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin in type 2 diabetes

Drugs of today (Barcelona, Spain : 1998), 2010-02, Vol.46 (2), p.101-108

Billiones, Raquel

2010

Link zum Volltext

Verfügbarkeit prüfen

New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI 53)

Der Internist (Berlin), 2014-07, Vol.55 (7), p.859-862

2014

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin + metformin. Mostly disadvantages

Prescrire international, 2013-02, Vol.22 (135), p.40-40

2013

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin and tuberculosis

Prescrire international, 2013-01, Vol.22 (134), p.17-17

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 32

Suche als RSS-Feed

Aktive Filter

KollektionSage Journals

Nur zeigenGeprüft (Peer-Review)

KollektionMEDLINE

ThemaDiabetes Mellitus, Type 2 - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(26)

Publikationsform

Artikel
(31)
magazinearticle
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Adamantane - Analogs & Derivatives
(32)
Humans
(32)
Dipeptides - Therapeutic Use
(28)
Adamantane - Therapeutic Use
(27)
Dipeptidyl-Peptidase Iv Inhibitors - Therapeutic Use
(24)
Life Sciences & Biomedicine
(24)
Science & Technology
(24)
Endocrinology & Metabolism
(19)
Hypoglycemic Agents - Therapeutic Use
(19)
Treatment Outcome
(16)
Diabetes
(15)
Female
(15)
Male
(14)
Adamantane - Adverse Effects
(12)
Diabetes Mellitus
(12)
Dipeptides - Adverse Effects
(12)
Middle Aged
(12)
Aged
(11)
Dipeptidyl-Peptidase Iv Inhibitors - Adverse Effects
(11)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)

Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment

Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open‐label randomized controlled study (the SMART study)

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks

Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study

Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies

Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR‐TIMI 53 outcome study

Baseline differences in the SAVOR trial

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes

Saxagliptin and Heart Failure in the SAVOR-TIMI 53 Trial: Reflections on the Bradford Hill Criteria

Saxagliptin efficacy

Saxagliptin: A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes

Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

No heart risk--or benefit--from diabetes drug Onglyza

DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia

Saxagliptin in type 2 diabetes

New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI 53)

Saxagliptin + metformin. Mostly disadvantages

Saxagliptin and tuberculosis

Aktive Filter

Suchergebnisse filtern